{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:34Z","timestamp":1786984294046,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Propofol is an intravenous anesthetic widely used for induction and maintenance of anesthesia and sedation. Despite its well-established efficacy and routine clinical use, multiple reports have described adverse reactions ranging from mild events to life-threatening complications. Pharmacovigilance databases provide valuable insight into such real-world experiences. This study provides an updated global overview of adverse drug reactions (ADRs) associated with propofol using data from the World Health Organization (WHO) VigiAccess platform. A retrospective descriptive study was performed using publicly available data from the WHO-VigiAccess database, retrieved on October 26,2025, covering all spontaneous reports available from the inception of WHO pharmacovigilance reporting through the search date. ADRs were summarized according to the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class and analyzed by geographical region, sex, and age group. No individual case review, disproportionality analysis, or causality assessment was performed. VigiAccess listed 45 354 ADR reports for propofol. Of the 45,354 ADR reports, skin and subcutaneous tissue disorders (12%), vascular disorders (12%), general disorders and administration site conditions (11%), nervous system disorders (9%), respiratory disorders (9%), immune disorders (8%), and cardiac disorders (8%) were most frequently reported. Europe and the Americas accounted for the largest proportion of reports. Male patients represented a slightly higher proportion than females, and adults aged 45 to 64 years constituted the most frequently reported age group. Temporal analysis revealed a continuous increase in reporting over the past 2 decades. This descriptive pharmacovigilance overview highlights the broad spectrum of spontaneously reported ADRs associated with propofol and emphasizes the importance of continued pharmacovigilance and post-marketing safety monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050189","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:02:44Z","timestamp":1786730564000},"page":"e50189","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Global pharmacovigilance overview of adverse drug reactions associated with propofol"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0636-7685","authenticated-orcid":false,"given":"Nasser M.","family":"Alorfi","sequence":"first","affiliation":[{"name":"Pharmacology and Toxicology Department, College of Pharmacy, Umm Al\u2010Qura University, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Aldabbagh","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Dr. Soliman Fakeeh Hospital, Fakeeh Care Group, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour M.","family":"Alourfi","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Dr. Soliman Fakeeh Hospital, Fakeeh Care Group, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed Saleh","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Al Ghamdi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Abdullah","family":"Niyazi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, East Jeddah Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser M.","family":"Aldekhail","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, Nursing and Medical Sciences, Riyadh Elm University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustfa Faisal","family":"Alkhanani","sequence":"additional","affiliation":[{"name":"Biology Department, College of Sciences, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihal Abdalla","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Ajman University, Ajman, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrhman M.","family":"Alansari","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Services, King Salman Medical City, Madinah Health Cluster, Madinah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq Omar","family":"Ali","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Services, Ohoud, Madinah Health Cluster, Madinah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris A.","family":"Alsolami","sequence":"additional","affiliation":[{"name":"Kholais General Hospital, Makkah Cluster, Ministry of Health, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah H.O.","family":"Zarroug","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Department, College of Pharmacy, Umm Al\u2010Qura University, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana K.","family":"Abdalla","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1055\/s-0040-1707287","article-title":"Syntheses of analogues of propofol: a review.","volume":"52","author":"Dimitrov","year":"2020","journal-title":"Synthesis"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.21873\/invivo.12532","article-title":"Effects of the hypnotic alkylphenol derivative propofol on breast cancer progression. a focus on preclinical and clinical studies.","volume":"35","author":"Bimonte","year":"2021","journal-title":"In Vivo"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.61919\/5we8wz86","article-title":"Comparing propofol and sevoflurane for faster recovery in pediatrics.","volume":"3","author":"Hamad","year":"2025","journal-title":"J Health Wellness Community Res"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s40262-018-0672-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of propofol.","volume":"57","author":"Sahinovic","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-3-540-74806-9_11","article-title":"Propofol.","author":"Vanlersberghe","year":"2008","journal-title":"Handb Exp Pharmacol"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.2174\/1381612043382846","article-title":"Propofol: therapeutic indications and side-effects.","volume":"10","author":"Marik","year":"2004","journal-title":"Curr Pharm Des"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4097\/kja.20162","article-title":"Intraoperative refractory status epilepticus caused by propofol -a case report.","volume":"74","author":"Kumar","year":"2021","journal-title":"Korean J Anesthesiol"},{"key":"R10-20260817","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3390\/pharmaceutics16121615","article-title":"Pharmacodynamic model of the hemodynamic effects of propofol and remifentanil and their interaction with noxious stimulation.","volume":"16","author":"Garraza-Obaldia","year":"2024","journal-title":"Pharmaceutics"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"296217","DOI":"10.3389\/fvets.2018.00053","article-title":"Anesthesia-associated relative hypovolemia: mechanisms, monitoring, and treatment considerations.","volume":"5","author":"Noel-Morgan","year":"2018","journal-title":"Front Vet Sci"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/bja\/aew126","article-title":"The effect of propofol on haemodynamics: cardiac output, venous return, mean systemic filling pressure, and vascular resistances.","volume":"116","author":"De Wit","year":"2016","journal-title":"Br J Anaesth"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4097\/kjae.2002.43.1.38","article-title":"Effect of propofol anesthesia on blood coagulation and fibrinolysis: an assessment using thromboelastograph at clipping of cerebral aneurysms.","volume":"43","author":"Kim","year":"2002","journal-title":"Korean J Anesthesiol"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.hroo.2022.02.011","article-title":"Deep sedation with propofol in patients undergoing left atrial ablation procedures-Is it safe?","volume":"3","author":"Foerschner","year":"2022","journal-title":"Heart Rhythm O2"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4103\/am.am_95_20","article-title":"Prevalence of side effects of propofol anesthesia among adult and pediatric patients undergoing surgery.","volume":"17","author":"Alsaeiti","year":"2020","journal-title":"Apollo Med"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17512433.2021.1919084","article-title":"Pharmacological control of pain during propofol injection: a systematic review and meta-analysis.","volume":"14","author":"Bakhtiari","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12663-014-0676-y","article-title":"Comparitive evaluation of propofol and midazolam as conscious sedatives in minor oral surgery.","volume":"14","author":"Hari Keerthy","year":"2015","journal-title":"J Maxillofac Oral Surg"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/0019-5154.92692","article-title":"Propofol extravasation and tissue necrosis.","volume":"57","author":"Basak","year":"2012","journal-title":"Indian J Dermatol"},{"key":"R20-20260817","first-page":"807","article-title":"Rare side effects of propofol administration-case report and a brief literature review.","volume":"5","author":"Ismail","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000533327","article-title":"Propofol-associated urine discoloration: systematic literature review.","volume":"108","author":"Lasica","year":"2023","journal-title":"Pharmacology"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00003643-200401000-00012","article-title":"Epileptiform movements associated with re-exposure to propofol.","volume":"21","author":"Puranik","year":"2004","journal-title":"Eur J Anaesthesiol"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/FTD.0000000000000073","article-title":"Hypertriglyceridemia, lipemia, and elevated liver enzymes associated with prolonged propofol anesthesia for craniotomy.","volume":"36","author":"Bowdle","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R25-20260817","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1053\/j.ajkd.2004.08.036","article-title":"Propofol infusion syndrome: an unusual cause of renal failure.","volume":"44","author":"Casserly","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R26-20260817","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/10601330009005314","article-title":"Can propofol cause dystonia and movement disorders?","volume":"17","author":"Al-Humaidan","year":"2000","journal-title":"Clin Res Regul Aff"},{"key":"R27-20260817","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1017\/cjn.2022.4","article-title":"Propofol withdrawal dyskinesia in a Parkinson\u2019s disease patient with levodopa-induced dyskinesia.","volume":"50","author":"Nakajima","year":"2023","journal-title":"Can J Neurol Sci"},{"key":"R28-20260817","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00002018-200831040-00003","article-title":"Propofol infusion syndrome: an overview of a perplexing disease.","volume":"31","author":"Fodale","year":"2008","journal-title":"Drug Saf"},{"key":"R29-20260817","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MJT.0b013e3181ed837a","article-title":"Propofol infusion syndrome.","volume":"17","author":"Wong","year":"2010","journal-title":"Am J Ther"},{"key":"R30-20260817","first-page":"260385","article-title":"Propofol infusion syndrome in adults: a clinical update.","volume":"2015","author":"Mirrakhimov","year":"2015","journal-title":"Crit Care Res Pract"},{"key":"R31-20260817","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2044.2007.05055.x","article-title":"Propofol infusion syndrome.","volume":"62","author":"Kam","year":"2007","journal-title":"Anaesthesia"},{"key":"R32-20260817","doi-asserted-by":"crossref","first-page":"d1110","DOI":"10.1136\/bmj.d1110","article-title":"Prevention of pain on injection of propofol: systematic review and meta-analysis.","volume":"342","author":"Jalota","year":"2011","journal-title":"BMJ"},{"key":"R33-20260817","first-page":"963","article-title":"Prevention of pain on injection with propofol: a quantitative systematic review.","volume":"90","author":"Picard","year":"2000","journal-title":"Anesth Analg"},{"key":"R35-20260817","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1034\/j.1399-6576.2003.00228.x","article-title":"Effects of propofol on bronchoconstriction and bradycardia induced by vagal nerve stimulation.","volume":"47","author":"Hashiba","year":"2003","journal-title":"Acta Anaesthesiol Scand"},{"key":"R36-20260817","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1213\/ane.0b013e318168b443","article-title":"Respiratory depression after neuraxial opioids in the obstetric setting.","volume":"107","author":"Carvalho","year":"2008","journal-title":"Anesth Analg"},{"key":"R37-20260817","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00148581-200305090-00004","article-title":"Effects of obstetric analgesics and anesthetics on the neonate.","volume":"5","author":"Mattingly","year":"2003","journal-title":"Paediatr Drugs"},{"key":"R38-20260817","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1080\/02648725.2023.2202541","article-title":"Propofol-associated serious adverse events: an analysis of the FAERS database.","volume":"40","author":"Xuan","year":"2024","journal-title":"Biotechnol Genet Eng Rev"},{"key":"R39-20260817","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/ph14080783","article-title":"Comparative safety profiles of sedatives commonly used in clinical practice: a 10-year nationwide pharmacovigilance study in Korea.","volume":"14","author":"Choi","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"R40-20260817","doi-asserted-by":"crossref","first-page":"542","DOI":"10.5414\/CP204796","article-title":"Cardiovascular toxicity associated with sedative drug use: post-market pharmacovigilance study with disproportionality analysis.","volume":"63","author":"Ye","year":"2025","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R42-20260817","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.annemergmed.2014.06.019","article-title":"Managing propofol-induced hypoventilation.","volume":"65","author":"Green","year":"2015","journal-title":"Ann Emerg Med"},{"key":"R43-20260817","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1345\/aph.1A321","article-title":"Propofol infusion syndrome in critically ill patients.","volume":"36","author":"Kang","year":"2002","journal-title":"Ann Pharmacother"},{"key":"R44-20260817","first-page":"200","article-title":"Propofol infusion syndrome.","volume":"13","author":"Loh","year":"2013","journal-title":"Contin Educ Anaesth Crit Care Pain"},{"key":"R45-20260817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-015-1112-5","article-title":"Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports.","volume":"19","author":"Kraj\u010dov\u00e1","year":"2015","journal-title":"Crit Care"},{"key":"R46-20260817","doi-asserted-by":"crossref","first-page":"502577","DOI":"10.1016\/j.rce.2026.502577","article-title":"Notification of suspected adverse drug reactions by nurses to a hospital pharmacovigilance program. Retrospective descriptive study.","volume":"226","author":"Ord\u00f3\u00f1ez-Rufat","year":"2026","journal-title":"Rev Clin Esp (Barc)"},{"key":"R47-20260817","doi-asserted-by":"crossref","first-page":"1427772","DOI":"10.3389\/fphar.2024.1427772","article-title":"Spontaneous adverse drug reactions reported in a thirteen-year pharmacovigilance program in a tertiary university hospital.","volume":"15","author":"Montan\u00e9","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:01:43Z","timestamp":1786982503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050189"}},"subtitle":["A descriptive pharmacovigilance study using WHO-VigiAccess data"],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":41,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050189","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"2026-04-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}